CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute ...
How will the company's earnings guidance be adjusted in light of the clinical updates and expected expenses?
What potential partnership or licensing opportunities could arise from positive trial results?
How does CalciMedica's current valuation compare to peers developing therapies for AKI and acute pancreatitis?
27 days ago